Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03625323
Title Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Immutep S.A.
Indications

laryngeal squamous cell carcinoma

oropharynx cancer

head and neck squamous cell carcinoma

oral squamous cell carcinoma

lung non-small cell carcinoma

hypopharynx cancer

Therapies

Eftilagimod alpha + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | GBR | ESP | AUS

Additional content available in CKB BOOST